We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 70.00
Bid: 70.00
Ask: 72.60
Change: 5.60 (8.70%)
Spread: 2.60 (3.714%)
Open: 63.00
High: 73.80
Low: 63.00
Prev. Close: 64.40
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DHSC Dispute Update

21 May 2021 07:00

RNS Number : 3629Z
Novacyt S.A.
21 May 2021
 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

DHSC Dispute Update

 

Paris, France and Camberley, UK - 21 May 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update to its ongoing dispute with the Department of Health and Social Care ("DHSC").

 

On 9 April 2021, Novacyt announced that it was in dispute with the DHSC in relation to its second supply contract and that this may have a material impact on Q4 2020 revenues. In the same announcement it was also noted that approximately 50% of Q1 2021 revenue was driven by sales to the DHSC. The dispute may now have a material impact on these Q1 2021 revenues from the DHSC.

 

The Company has taken legal advice in relation to the dispute and believes it has strong grounds to assert its contractual rights.

 

The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

- End -

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com ; y.petit@allegrafinance.com

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com/ Novacyt.group@fticonsulting.com 

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCURAKRAKUVUAR
Date   Source Headline
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20202:06 pmRNSSecond Price Monitoring Extn
9th Apr 20202:00 pmRNSPrice Monitoring Extension
9th Apr 20209:05 amRNSSecond Price Monitoring Extn
9th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20204:42 pmRNSSecond Price Monitoring Extn
8th Apr 20204:37 pmRNSPrice Monitoring Extension
8th Apr 20202:05 pmRNSSecond Price Monitoring Extn
8th Apr 20202:00 pmRNSPrice Monitoring Extension
8th Apr 20209:05 amRNSSecond Price Monitoring Extn
8th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSPartnership with AZ, GSK & University of Cambridge
8th Apr 20207:00 amRNSCOVID test eligible for WHO Emergency Use Listing
6th Apr 20207:00 amRNSCOVID-19 diagnostic regulatory update
3rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
3rd Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 20204:00 pmRNSLiquidity Agreement and Total Voting Rights
30th Mar 20207:00 amRNSCoronavirus test update
25th Mar 20207:00 amRNSManufacturing agreement signed with Yourgene
25th Mar 20207:00 amRNSGlobal distribution agreement with Bruker
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
23rd Mar 20204:42 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
23rd Mar 20202:06 pmRNSSecond Price Monitoring Extn
23rd Mar 20202:01 pmRNSPrice Monitoring Extension
23rd Mar 202011:06 amRNSSecond Price Monitoring Extn
23rd Mar 202011:00 amRNSPrice Monitoring Extension
23rd Mar 20207:00 amRNSFDA Emergency Use Authorization for COVID-19 test
20th Mar 20203:00 pmRNSCoronavirus test update
16th Mar 20202:05 pmRNSSecond Price Monitoring Extn
16th Mar 20202:01 pmRNSPrice Monitoring Extension
16th Mar 20209:05 amRNSSecond Price Monitoring Extn
16th Mar 20209:00 amRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSCoronavirus test update
11th Mar 20202:05 pmRNSSecond Price Monitoring Extn
11th Mar 20202:00 pmRNSPrice Monitoring Extension
6th Mar 20204:41 pmRNSSecond Price Monitoring Extn
6th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 20202:05 pmRNSSecond Price Monitoring Extn
6th Mar 20202:00 pmRNSPrice Monitoring Extension
6th Mar 202011:05 amRNSSecond Price Monitoring Extn
6th Mar 202011:00 amRNSPrice Monitoring Extension
5th Mar 20205:09 pmRNSHoldings in Company
5th Mar 20202:05 pmRNSSecond Price Monitoring Extn
5th Mar 20202:00 pmRNSPrice Monitoring Extension
4th Mar 20204:40 pmRNSSecond Price Monitoring Extn
4th Mar 20204:35 pmRNSPrice Monitoring Extension
2nd Mar 20201:15 pmRNSLiquidity Agreement Update and Total Voting Rights
28th Feb 20204:40 pmRNSSecond Price Monitoring Extn
28th Feb 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.